Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer.

IF 6.4 1区 医学 Q1 ONCOLOGY
Richard Choo, Kimberly Corbin, Kenneth Merrell, Bradley Stish, Thomas M Pisansky, Brian J Davis, Adam Amundson, David W Hillman, Cecilia Mitchell, William Wong, Carlos Vargas, Jean Claude Rwigema, Sameer Keole, Sujay Vora, Thomas Daniels
{"title":"Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer.","authors":"Richard Choo, Kimberly Corbin, Kenneth Merrell, Bradley Stish, Thomas M Pisansky, Brian J Davis, Adam Amundson, David W Hillman, Cecilia Mitchell, William Wong, Carlos Vargas, Jean Claude Rwigema, Sameer Keole, Sujay Vora, Thomas Daniels","doi":"10.1016/j.ijrobp.2024.11.115","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To assess the efficacy of moderately hypofractionated intensity-modulated proton therapy (IMPT) targeting the prostate/seminal vesicles and pelvic lymph nodes for high-risk (HR) or unfavorable intermediate-risk (UIR) prostate cancer (PCa) MATERIALS/METHODS: A prospective study (ClinicalTrials.gov: NCTXXX) of moderately hypofractionated IMPT accrued a target sample size of 56 patients with HR or UIR-PCa . The prostate/seminal vesicles and pelvic lymph nodes were treated simultaneously with 67.5 Gy and 45 Gy, respectively, in 25 daily fractions. All received androgen deprivation therapy (ADT). Its primary objective was late gastrointestinal (GI) and genitourinary (GU) adverse events (AEs), and secondary objectives were a recurrence-free rate (RFR) including freedom from PSA relapse and disease-free survival (DFS) at 5 years. PSA and AEs were evaluated at 3, 6, and 12 months post-IMPT, then every 6 months for 5 years and then yearly thereafter. The actuarial rates of late GI and GU AEs, RFR, and DFS were estimated with Kaplan-Meier method.</p><p><strong>Results: </strong>Median age was 75 years. Median PSA was 10.5 ng/mL. Fifty-three patients had HR-PCa; 2 had UIR-PCa. Median ADT duration was 18 months. Median follow-up was 62 months. Late grade ≥ 2 and 3 GI AEs at 5 years were 16% and 4%, respectively. Late grade ≥ 2 and 3 GU AEs at 5 years were 41% and 0%, respectively. None had a grade ≥ 4 late AE. At 5 years, RFR and DFS were 90% and 89%, respectively. Seven patients had PCa recurrence, all detected by PSA relapse initially. Three patients died with PSA < 0.1 ng/mL at last follow-up. None died of PCa or treatment-related AEs.</p><p><strong>Conclusions: </strong>This regimen of moderately hypofractionated IMPT for HR or UIR-PCa yielded encouraging 5-year RFR, DFS, and late AE outcomes. A phase III study is needed to assess any therapeutic gain of IMPT compared with photon-based radiotherapy.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.11.115","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To assess the efficacy of moderately hypofractionated intensity-modulated proton therapy (IMPT) targeting the prostate/seminal vesicles and pelvic lymph nodes for high-risk (HR) or unfavorable intermediate-risk (UIR) prostate cancer (PCa) MATERIALS/METHODS: A prospective study (ClinicalTrials.gov: NCTXXX) of moderately hypofractionated IMPT accrued a target sample size of 56 patients with HR or UIR-PCa . The prostate/seminal vesicles and pelvic lymph nodes were treated simultaneously with 67.5 Gy and 45 Gy, respectively, in 25 daily fractions. All received androgen deprivation therapy (ADT). Its primary objective was late gastrointestinal (GI) and genitourinary (GU) adverse events (AEs), and secondary objectives were a recurrence-free rate (RFR) including freedom from PSA relapse and disease-free survival (DFS) at 5 years. PSA and AEs were evaluated at 3, 6, and 12 months post-IMPT, then every 6 months for 5 years and then yearly thereafter. The actuarial rates of late GI and GU AEs, RFR, and DFS were estimated with Kaplan-Meier method.

Results: Median age was 75 years. Median PSA was 10.5 ng/mL. Fifty-three patients had HR-PCa; 2 had UIR-PCa. Median ADT duration was 18 months. Median follow-up was 62 months. Late grade ≥ 2 and 3 GI AEs at 5 years were 16% and 4%, respectively. Late grade ≥ 2 and 3 GU AEs at 5 years were 41% and 0%, respectively. None had a grade ≥ 4 late AE. At 5 years, RFR and DFS were 90% and 89%, respectively. Seven patients had PCa recurrence, all detected by PSA relapse initially. Three patients died with PSA < 0.1 ng/mL at last follow-up. None died of PCa or treatment-related AEs.

Conclusions: This regimen of moderately hypofractionated IMPT for HR or UIR-PCa yielded encouraging 5-year RFR, DFS, and late AE outcomes. A phase III study is needed to assess any therapeutic gain of IMPT compared with photon-based radiotherapy.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信